Analysis of Virus Clearance for Biotechnology Manufacturing Processes from Early to Late Phase Development

References

1. 1.↵
   FDA-Guidance Investigational New Drug (IND) Application. https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application (accessed 02/02/2024).
2. 2.↵
   1. Barone P. W.,
   2. Wiebe M. E.,
   3. Leung J. C.,
   4. Hussein I. T. M.,
   5. Keumurian F. J.,
   6. Bouressa J.,
   7. Brussel A.,
   8. Chen D.,
   9. Chong M.,
   10. Dehghani H.,
   11. Gerentes L.,
   12. Gilbert J.,
   13. Gold D.,
   14. Kiss R.,
   15. Kreil T. R.,
   16. Labatut R.,
   17. Li Y.,
   18. Müllberg J.,
   19. Mallet L.,
   20. Menzel C.,
   21. Moody M.,
   22. Monpoeho S.,
   23. Murphy M.,
   24. Plavsic M.,
   25. Roth N. J.,
   26. Roush D.,
   27. Ruffing M.,
   28. Schicho R.,
   29. Snyder R.,
   30. Stark D.,
   31. Zhang C.,
   32. Wolfrum J.,
   33. Sinskey A. J.,
   34. Springs S. L.

   Viral Contamination in Biologic Manufacture and Implications for Emerging Therapies. Nat. Biotechnol. 2020, 38 (5), 563–572.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Merten O.-W.

   Virus Contaminations of Cell Cultures – A Biotechnological View. Cytotechnology 2002, 39 (2), 91–116.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   1. Lubiniecki A. S.

   Evolution of Approaches to Viral Safety Issues for Biological Products. PDA J. Pharm. Sci. Technol. 2011, 65 (6), 547–556.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Adamson S. R.

   Experiences of Virus, Retrovirus and Retrovirus-like Particles in Chinese Hamster Ovary (CHO) and Hybridoma Cells Used for Production of Protein Therapeutics. Dev. Biol. Stand. 1998, 93, 89–96.

   OpenUrlPubMedWeb of Science
6. 6.↵
   1. Victoria J. G.,
   2. Wang C.,
   3. Jones M. S.,
   4. Jaing C.,
   5. McLoughlin K.,
   6. Gardner S.,
   7. Delwart E. L.

   Viral Nucleic Acids in Live-Attenuated Vaccines: Detection of Minority Variants and an Adventitious Virus. J. Virol. 2010, 84 (12), 6033–6040.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Shah K.,
   2. Nathanson N.

   Human Exposure to SV40: Review and Comment. Am. J. Epidemiol. 1976, 103 (1), 1–12.

   OpenUrlPubMedWeb of Science
8. 8.↵
   1. Weinberg P. D.,
   2. Hounshell J.,
   3. Sherman L. A.,
   4. Godwin J.,
   5. Ali S.,
   6. Tomori C.,
   7. Bennett C. L.

   Legal, Financial, and Public Health Consequences of HIV Contamination of Blood and Blood Products in the 1980s and 1990s. Ann. Intern. Med. 2002, 136 (4), 312–319.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   International Conference for Harmonisation, Harmonised Guideline Q5A(R2) Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin. ICH: Geneva, 2023.
10. 10.↵
    1. Miesegaes G.,
    2. Lute S.,
    3. Brorson K.

    Analysis of Viral Clearance Unit Operations for Monoclonal Antibodies. Biotechnol. Bioeng. 2010, 106 (2), 238–246.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Ajayi O. O.,
    2. Johnson S. A.,
    3. Faison T.,
    4. Azer N.,
    5. Cullinan J. L.,
    6. Dement-Brown J.,
    7. Lute S. C.

    An Updated Analysis of Viral Clearance Unit Operations for Biotechnology Manufacturing. Curr. Res. Biotechnol. 2022, 4, 190–202.

    OpenUrl
12. 12.↵
    U.S. Food and Drug Administration. Pharmaceutical Quality - Chemistry, Manufacturing & Controls. | PQ/CMC. https://www.fda.gov/industry/fda-data-standards-advisory-board/pharmaceutical-quality-chemistry-manufacturing-controls-pqcmc (accessed 10/01/2024).
13. 13.↵
    1. Miesegaes G.,
    2. Lute S.,
    3. Aranha H.,
    4. Brorson K.

    Virus Retentive Filters. In Encyclopedia of Industrial Biotechnology; Wiley, 2009.
14. 14.↵
    1. Pan C.,
    2. Becerra-Arteaga A.,
    3. Tran B.,
    4. Chinn M.,
    5. Wang H.,
    6. Chen Q.,
    7. Lutz H.,
    8. Zhang M.

    Characterizing and Enhancing Virus Removal by Protein A Chromatography. Biotechnol. Bioeng. 2019, 116 (4), 846–856.

    OpenUrl
15. 15.↵
    1. Brorson K.,
    2. Krejci S.,
    3. Lee K.,
    4. Hamilton E.,
    5. Stein K.,
    6. Xu Y.

    Bracketed Generic Inactivation of Rodent Retroviruses by Low pH Treatment for Monoclonal Antibodies and Recombinant Proteins. Biotechnol. Bioeng. 2003, 82 (3), 321–329.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Johnson S. A.,
    2. Chen S.,
    3. Bolton G.,
    4. Chen Q.,
    5. Lute S.,
    6. Fisher J.,
    7. Brorson K.

    Virus Filtration: A Review of Current and Future Practices in Bioprocessing. Biotechnol. Bioeng. 2021, 119 (3), 743–761.

    OpenUrl
17. 17.↵
    1. Daya J.,
    2. Cusick V.,
    3. Mattila J.

    Characterization of Ionic Strength for X-MuLV Inactivation by Low pH Treatment for Monoclonal Antibody Purification. Biotechnol. Bioeng. 2023, 120 (6), 1605–1613.

    OpenUrl
18. 18.↵
    1. Chinniah S.,
    2. Hinckley P.,
    3. Connell-Crowley L.

    Characterization of Operating Parameters for XMuLV Inactivation by Low pH Treatment. Biotechnol. Prog. 2016, 32 (1), 89–97.

    OpenUrl
19. 19.↵
    1. Mattila J.,
    2. Clark M.,
    3. Liu S.,
    4. Pieracci J.,
    5. Gervais T. R.,
    6. Wilson E.,
    7. Galperina O.,
    8. Li X.,
    9. Roush D.,
    10. Zoeller K.,
    11. Brough H.,
    12. Simpson-Platre C.

    Retrospective Evaluation of Low-pH Viral Inactivation and Viral Filtration Data from a Multiple Company Collaboration. PDA J. Pharm. Sci. Technol. 2016, 70 (3), 293–299.

    OpenUrlAbstract/FREE Full Text
20. 20.↵
    European Parliament, Council of the European Union. Regulation (EC) No. 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC. 2006.
21. 21.↵
    1. Farcet J.-B.,
    2. Kindermann J.,
    3. Karbiener M.,
    4. Kreil T. R.

    Development of a Triton X-100 Replacement for Effective Virus Inactivation in Biotechnology Processes. Eng. Rep. 2019, 1 (5), e12078.

    OpenUrl
22. 22.↵
    1. Farcet J.-B.,
    2. Karbiener M.,
    3. Zelger L.,
    4. Kindermann J.,
    5. Kreil T. R.

    Detergent-Mediated Virus Inactivation in Biotechnological Matrices: More than Just CMC. Int. J. Mol. Sci. 2023, 24 (9), 7920.

    OpenUrlPubMed
23. 23.↵
    1. Conley L.,
    2. Tao Y.,
    3. Henry A.,
    4. Koepf E.,
    5. Cecchini D.,
    6. Pieracci J.,
    7. Ghose S.

    Evaluation of Eco-Friendly Zwitterionic Detergents for Enveloped Virus Inactivation. Biotechnol. Bioeng. 2017, 114 (4), 813–820.

    OpenUrl
24. 24.↵
    1. Brorson K.,
    2. Lute S.,
    3. Haque M.,
    4. Martin J.,
    5. Sato T.,
    6. Moroe I.,
    7. Morgan M.,
    8. Krishnan M.,
    9. Campbell J.,
    10. Genest P.,
    11. Parrella J.,
    12. Dolan S.,
    13. Martin S.,
    14. Tarrach K.,
    15. Levy R.

    ; PDA Virus Filter Task Force. A Consensus Rating Method for Small Virus-Retentive Filters. II. Method Evaluation. PDA J. Pharm. Sci. Technol. 2008, 62 (5), 334–343.

    OpenUrlAbstract/FREE Full Text
25. 25.↵
    1. Roth N. J.,
    2. Dichtelmüller H. O.,
    3. Fabbrizzi F.,
    4. Flechsig E.,
    5. Gröner A.,
    6. Gustafson M.,
    7. Jorquera J. I.,
    8. Kreil T. R.,
    9. Misztela D.,
    10. Moretti E.,
    11. Moscardini M.,
    12. Poelsler G.,
    13. More J.,
    14. Roberts P.,
    15. Wieser A.,
    16. Gajardo R.

    Nanofiltration as a Robust Method Contributing to Viral Safety of Plasma-Derived Therapeutics: 20 Years' Experience of the Plasma Protein Manufacturers. Transfusion 2020, 60 (11), 2661–2674.

    OpenUrl
26. 26.↵
    1. Roush D.,
    2. Ma J.

    Viral Clearance Using Traditional, Well-Understood Unit Operations Session 1.2: Virus-Retentive Filtration. PDA J. Pharm. Sci. Technol. 2016, 70 (5), 417–427.

    OpenUrlFREE Full Text
27. 27.↵
    1. Chen D.

    Viral Clearance Using Traditional, Well-Understood Unit Operations (Session I): Virus-Retentive Filtration. PDA J. Pharm. Sci. Technol. 2014, 68 (1), 38–50.

    OpenUrlFREE Full Text
28. 28.↵
    1. Bolton G. R.,
    2. Spector S.,
    3. Lacasse D.

    Increasing the Capacity of Parvovirus-Retentive Membranes: Performance of the Viresolve Prefilter. Biotechnol. Appl. Biochem. 2006, 43 (Pt 1), 55–63.

    OpenUrlPubMed
29. 29.↵
    1. Billups M,
    2. Minervini M.,
    3. Holstein M.,
    4. Feroz H.,
    5. Ranjan S.,
    6. Hung J.,
    7. Bao H.,
    8. Li Z. J.,
    9. Ghose S.,
    10. Zydney A. L.

    Role of Membrane Structure on the Filtrate Flux During Monoclonal Antibody Filtration through Virus Retentive Membranes. Biotechnol. Prog. 2022, 38 (2), e3231.

    OpenUrl
30. 30.↵
    1. LaCasse D.,
    2. Lute S.,
    3. Fiadeiro M.,
    4. Basha J.,
    5. Stork M.,
    6. Brorson K.,
    7. Godavarti R.,
    8. Gallo C.

    Mechanistic Failure Mode Investigation and Resolution of Parvovirus Retentive Filters. Biotechnol. Prog. 2016, 32 (4), 959–970.

    OpenUrl
31. 31.↵
    1. Leisi R.,
    2. Widmer E.,
    3. Gooch B.,
    4. Roth N. J.,
    5. Ros C.

    Mechanistic Insights into Flow-Dependent Virus Retention in Different Nanofilter Membranes. J. Membr. Sci. 2021, 636, 119548.

    OpenUrl
32. 32.↵
    1. Lute S.,
    2. Kozaili J.,
    3. Johnson S.,
    4. Kobayashi K.,
    5. Strauss D.

    Development of Small-Scale Models to Understand the Impact of Continuous Downstream Bioprocessing on Integrated Virus Filtration. Biotechnol. Prog. 2020, 36 (3), e2962.

    OpenUrl
33. 33.↵
    1. Lund L. N.,
    2. Gustavsson P.-E.,
    3. Michael R.,
    4. Lindgren J.,
    5. Nørskov-Lauritsen L.,
    6. Lund M.,
    7. Houen G.,
    8. Staby A.,
    9. St. Hilaire P.M.

    Novel Peptide Ligand with High Binding Capacity for Antibody Purification. J. Chromatogr. A 2012, 1225 158–167.

    OpenUrlPubMed
34. 34.↵
    1. Hubbard B.

    Viral Clearance by Traditional Operations with Significant Knowledge Gaps (Session II): Protein A Chromatography. PDA J. Pharm. Sci. Technol. 2014, 68 (1), 13–16.

    OpenUrlFREE Full Text
35. 35.↵
    1. Lute S.,
    2. Norling L.,
    3. Hanson M.,
    4. Emery R.,
    5. Stinson D.,
    6. Padua K.,
    7. Blank G.,
    8. Chen Q.,
    9. Brorson K.

    Robustness of Virus Removal by Protein A Chromatography Is Independent of Media Lifetime. J. Chromatogr. A 2008, 1205 (1-2), 17–25.

    OpenUrlPubMed
36. 36.↵
    1. Remington M.,
    2. Kelly R.,
    3. Zehmer J.

    Viral Clearance by Protein A, Anion Exchange and Cation Exchange Chromatography Steps. Am. Pharm. Rev. 2015, https://www.americanpharmaceuticalreview.com/Featured-Articles/181836-Viral-Clearance-by-Protein-A-Anion-Exchange-and-Cation-Exchange-Chromatography-Steps/.
37. 37.↵
    1. Zhang M.,
    2. Miesegaes G. R.,
    3. Lee M.,
    4. Coleman D.,
    5. Yang B.,
    6. Trexler-Schmidt M.,
    7. Norling L.,
    8. Lester P.,
    9. Brorson K. A.,
    10. Chen Q.

    Quality by Design Approach for Viral Clearance by Protein A Chromatography. Biotechnol. Bioeng. 2014, 111 (1), 95–103.

    OpenUrl
38. 38.↵
    1. Bach J.,
    2. Connell-Crowley L.

    Clearance of the Rodent Retrovirus, XMuLV, by Protein A Chromatography. Biotechnol. Bioeng. 2015, 112 (4), 743–750.

    OpenUrl
39. 39.↵
    1. Strauss D. M.,
    2. Lute S.,
    3. Tebaykina Z.,
    4. Frey D. D.,
    5. Ho C.,
    6. Blank G. S.,
    7. Brorson K.,
    8. Chen Q.,
    9. Yang B.

    Understanding the Mechanism of Virus Removal by Q Sepharose Fast Flow Chromatography During the Purification of CHO-Cell Derived Biotherapeutics. Biotechnol. Bioeng. 2009, 104 (2), 371–380.

    OpenUrlCrossRefPubMed
40. 40.↵
    1. Leisi R.,
    2. Wolfisberg R.,
    3. Nowak T.,
    4. Caliaro O.,
    5. Hemmerle A.,
    6. Roth N. J.,
    7. Ros C.

    Impact of the Isoelectric Point of Model Parvoviruses on Viral Retention in Anion-Exchange Chromatography. Biotechnol. Bioeng. 2021, 118 (1), 116–129.

    OpenUrl
41. 41.↵
    1. Mi X.,
    2. Bromley E. K.,
    3. Joshi P. U.,
    4. Long F.,
    5. Heldt C. L.

    Virus Isoelectric Point Determination Using Single-Particle Chemical Force Microscopy. Langmuir 2020, 36 (1), 370–378.

    OpenUrlPubMed
42. 42.↵
    1. Sun Y.,
    2. Yu X.,
    3. Wang X.,
    4. Yuan K.,
    5. Wang G.,
    6. Hu L.,
    7. Zhang G.,
    8. Pei W.,
    9. Wang L.,
    10. Sun C.,
    11. Yang P.

    Bispecific Antibodies in Cancer Therapy: Target Selection and Regulatory Requirements. Acta Pharm. Sin. B 2023, 13 (9), 3583–3597.

    OpenUrlPubMed
43. 43.↵
    1. Li Y.

    Viral Removal by Column Chromatography in Downstream Processing of Monoclonal Antibodies. Protein Expression Purif. 2022, 198, 106131.

    OpenUrlPubMed
44. 44.↵
    1. Chen S.-T.,
    2. Xu W.,
    3. Cai K.,
    4. Ferreira G.,
    5. Ranil Wickramasinghe S.,
    6. Qian X.

    Factors Affecting Robustness of Anion Exchange Chromatography: Selective Retention of Minute Virus of Mice Using Membrane Media. J Chromatogr B: Anal. Technol. Biomed. Life Sci. 2022, 1210, 123449.

    OpenUrlPubMed
45. 45.↵
    1. Hung J.,
    2. Lam S. F.,
    3. Tan Z.,
    4. Choy D.,
    5. Chennamsetty N.,
    6. Lewandowski A.,
    7. Qi W.,
    8. Lynch M.,
    9. Ghose S.,
    10. Li Z. J.

    Impact of Virus-Antibody Interactions on Viral Clearance in Anion Exchange Chromatography. J. Chromatogr. A 2020, 1633, 461635.

    OpenUrlPubMed
46. 46.↵
    1. Roush D.

    Viral Clearance Using Traditional, Well-Understood Unit Operations (Session I): Anion Exchange Chromatography (AEX). PDA J. Pharm. Sci. Technol. 2014, 68 (1), 23–29.

    OpenUrlFREE Full Text
47. 47.↵
    1. Connell-Crowley L.,
    2. Larimore E. A.,
    3. Gillespie R.

    Using High Throughput Screening to Define Virus Clearance by Chromatography Resins. Biotechnol. Bioeng. 2013, 110 (7), 1984–1994.

    OpenUrl
48. 48.↵
    1. Miesegaes G. R.,
    2. Lute S.,
    3. Strauss D. M.,
    4. Read E. K.,
    5. Venkiteshwaran A.,
    6. Kreuzman A.,
    7. Shah R.,
    8. Shamlou P.,
    9. Chen D.,
    10. Brorson K.

    Monoclonal Antibody Capture and Viral Clearance by Cation Exchange Chromatography. Biotechnol. Bioeng. 2012, 109 (8), 2048–2058.

    OpenUrlPubMed
49. 49.↵
    1. Connell-Crowley L.,
    2. Nguyen T.,
    3. Bach J.,
    4. Chinniah S.,
    5. Bashiri H.,
    6. Gillespie R.,
    7. Moscariello J.,
    8. Hinckley P.,
    9. Dehghani H.,
    10. Vunnum S.,
    11. Vedantham G.

    Cation Exchange Chromatography Provides Effective Retrovirus Clearance for Antibody Purification Processes. Biotechnol. Bioeng. 2012, 109 (1), 157–165.

    OpenUrlPubMed
50. 50.↵
    1. Masuda Y.,
    2. Tsuda M.,
    3. Hashikawa-Muto C.,
    4. Takahashi Y.,
    5. Nonaka K.,
    6. Wakamatsu K.

    Cation Exchange Chromatography Performed in Overloaded Mode Is Effective in Removing Viruses During the Manufacturing of Monoclonal Antibodies. Biotechnol. Prog. 2019, 35 (5), e2858.

    OpenUrl
51. 51.↵
    1. Moo-Young M.

    1. Sun Y.,
    2. Shi Q.-H.,
    3. Zhang L.,
    4. Zhao G.-F.,
    5. Liu F.-F.

    2.47 - Adsorption and Chromatography. In Comprehensive Biotechnology, 2nd ed.; Moo-Young M., Ed.; Elsevier: Amsterdam, 2011; Vol. 2, pp 665–679,

    OpenUrl
52. 52.↵
    1. Ghose S.,
    2. Tao Y.,
    3. Conley L.,
    4. Cecchini D.

    Purification of Monoclonal Antibodies by Hydrophobic Interaction Chromatography Under No-Salt Conditions. mAbs 2013, 5 (5), 795–800.

    OpenUrlCrossRefPubMed
53. 53.↵
    1. Johnson S. A.,
    2. Walsh A.,
    3. Brown M. R.,
    4. Lute S. C.,
    5. Roush D. J.,
    6. Burnham M. S.,
    7. Brorson K. A.

    The Step-Wise Framework to Design a Chromatography-Based Hydrophobicity Assay for Viral Particles. J. Chromatogr. B 2017, 1061-1062, 430–437.

    OpenUrl
54. 54.↵
    1. Cetlin D.,
    2. Lynch M.,
    3. Li J.

    Monoclonal Antibody Aggregate Polish and Viral Clearance Using Hydrophobic-Interaction Chromatography. BioProcess Int. 2019, 17, 11–12.

    OpenUrl
55. 55.↵
    ASTM International, ASTM E2888- 12(2019) Standard Practice for Process for Inactivation of Rodent Retrovirus by pH. ASTM: West Conshohocken, PA, 2023.
56. 56.↵
    ASTM International, ASTM E3042-16 Standard Practice for Process Step to Inactivate Rodent Retrovirus with Triton X-100 Treatment. ASTM: West Conshohocken, PA, 2024.
57. 57.↵
    ASTM International, ASTM E3259-22 Standard Practice for Process to Remove Retroviruses by Small Virus Retentive Filters. ASTM: West Conshohocken, PA, 2023.
58. 58.↵
    FDA-Guidance Guidance for Industry - Changes to an Approved NDA or ANDA. https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application. (accessed 12/02/2024)